KR20240089762A - 점막염 치료용 조성물 및 방법 - Google Patents

점막염 치료용 조성물 및 방법 Download PDF

Info

Publication number
KR20240089762A
KR20240089762A KR1020247016007A KR20247016007A KR20240089762A KR 20240089762 A KR20240089762 A KR 20240089762A KR 1020247016007 A KR1020247016007 A KR 1020247016007A KR 20247016007 A KR20247016007 A KR 20247016007A KR 20240089762 A KR20240089762 A KR 20240089762A
Authority
KR
South Korea
Prior art keywords
human subject
mucositis
suffering
treating
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247016007A
Other languages
English (en)
Korean (ko)
Inventor
손기영
윤선영
Original Assignee
주식회사 엔지켐생명과학
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 엔지켐생명과학 filed Critical 주식회사 엔지켐생명과학
Publication of KR20240089762A publication Critical patent/KR20240089762A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247016007A 2021-10-18 2022-10-18 점막염 치료용 조성물 및 방법 Pending KR20240089762A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163257099P 2021-10-18 2021-10-18
US63/257,099 2021-10-18
PCT/IB2022/060007 WO2023067501A1 (en) 2021-10-18 2022-10-18 Compositions and methods for treating mucositis

Publications (1)

Publication Number Publication Date
KR20240089762A true KR20240089762A (ko) 2024-06-20

Family

ID=86057963

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247016007A Pending KR20240089762A (ko) 2021-10-18 2022-10-18 점막염 치료용 조성물 및 방법

Country Status (5)

Country Link
US (1) US20240415798A1 (https=)
EP (1) EP4419096A4 (https=)
JP (1) JP2024537906A (https=)
KR (1) KR20240089762A (https=)
WO (1) WO2023067501A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158322A0 (en) * 2001-04-18 2004-05-12 Prometic Biosciences Inc Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
KR20050118057A (ko) * 2004-04-24 2005-12-15 김상희 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품
US9808438B2 (en) * 2015-11-09 2017-11-07 Enzychem Lifesciences Corporation Method for treating mucositis
PL3716967T3 (pl) * 2017-11-30 2023-12-11 Enzychem Lifesciences Corporation Kompozycje do zapobiegania lub leczenia ostrej choroby popromiennej

Also Published As

Publication number Publication date
JP2024537906A (ja) 2024-10-16
EP4419096A4 (en) 2026-04-15
EP4419096A1 (en) 2024-08-28
US20240415798A1 (en) 2024-12-19
WO2023067501A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
Pfaffenrath et al. Efficacy and tolerability of amitriptylinoxide in the treatment of chronic tension‐type headache: a multi‐centre controlled study
EP4003327B1 (en) Compounds for use in the treatment of paroxysmal nocturnal haemoglobinuria (pnh)
EA025421B1 (ru) Лечение липодистрофии
EP4110326B1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
Ghantous et al. The efficiency of extended postoperative antibiotic prophylaxis in orthognathic surgery: a prospective, randomized, double-blind, placebo-controlled clinical trial
US20230338336A1 (en) Methods of treating conditions related to the s1p1 receptor
KR102053208B1 (ko) 진세노사이드 Rb1 및 Rb2를 유효성분으로 함유하는 근육 재생용 조성물
KR20240089762A (ko) 점막염 치료용 조성물 및 방법
EP3355909B1 (en) Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages
Lai et al. Levamisole aids in treatment of refractory oral candidiasis in two patients with thymoma associated with myasthenia gravis: report of two cases
Angriany et al. Acute pseudomembranous candidiasis accompanied with oral malignant lesions in HIV-Infected Patient: Case report
CN106999449B (zh) 用于治疗多汗症的方法
US20230330054A1 (en) Method for preventing or treating lung infection and lung inflammation
EP3646864A1 (en) Pharmaceutical containing pemafibrate
Laurent et al. [PP. 26.16] INDIVIDUAL DATA META-ANALYSIS IN 5507 SUBJECTS OF PERINDOPRIL 3.5 MG/AMLODIPINE 2.5 MG IN COMPARISON WITH RAS BLOCKER-MONOTHERAPIES
CN109939223B (zh) 一种白介素2在制备用于治疗寻常型天疱疮口腔糜烂药物的应用
CN114761015A (zh) 中性粒细胞弹性蛋白酶抑制剂在肺病中的用途
RU2821032C1 (ru) Способы лечения заболеваний, связанных с рецептором s1p1
RU2729425C2 (ru) Дозы панобиностата для множественной миеломы
Genovese et al. SAT0089 Safety and efficacy of LY3337641, a Bruton's tyrosine kinase inhibitor in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled, 2-part phase 2 study
Simonyi [PP. 26.18] MONITORING OF EFFECTIVENESS OF RAMIPRIL-AMLODIPINE FIXED COMBINATION IN METABOLIC SYNDROME, A NON-INTERVENTIONAL TRIAL (THE RAMSES STUDY)
CN113226374B (zh) 含氨氯地平、氯噻酮和醛固酮受体拮抗剂的药物组合物
Mikhailova et al. Pharmacokinetics of Angiotensin-Converting Enzyme Inhibitors in Elderly Patients with Arterial Hypertension
CN116916907A (zh) 用于治疗常染色体显性遗传性低钙血症1型(adh1)的三苯基溶钙化合物
NAGAI et al. Changes in blood pressure after the first dose of calcitonin (elcatonin)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000